Quotes on shares of ProMIS Neurosciences, a developer of drugs for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS), dropped more than 20% on Friday, July 26. The company announced a private placement for up to $122.7 million, along with positive data from clinical trials with healthy volunteers for its main…